First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.
Patnaik A, et al. Among authors: reif s.
Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.
Ann Oncol. 2016.
PMID: 27672108
Free PMC article.
Clinical Trial.